ADI 2020 will be ADI's first ever virtual conference, taking place 10-12 December.
Featured news and events
Alzheimer’s Disease International (ADI) launches the world’s most comprehensive report on dementia-related design and the built environment.
A new study in the Lancet Neurology has shown that blood phosphorylated tau 181 may be a promising biomarker for Alzheimer’s disease.
ADI welcomes three new Alzheimer associations, as well as new members to the ADI board.
ADI releases a position paper on the difficult decisions people with dementia, their families and carers are having to make around hospital admission and triage during COVID-19.
Professor Huali Wang of Alzheimer's Disease Chinese (ADC) explains how China has addressed the specific challenges of people living with dementia during COVID-19.
ADI's Global Perspective for February 2020 now available.
Roche announces end of DIAN-TU-001 study after it failed to meets its primary endpoint in people who are affected by early onset Autosomal dominant Alzheimer’s disease.
hinese Pharmaceutical Company Green Valley announces their drug Oligomannate (GV-971) has been granted conditional approval for the treatment of "mild to moderate Alzheimer's disease".
Biogen and Eisai have announced they will file for market approval for an investigational treatment for early Alzheimer’s disease.